Colorectal Cancer (MSI-H)
9
1
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
Assessment of a New Traction Device in Submucosal Dissection of Colorectal Lesions
Impact of Anxiety-Sleep Symptom Cluster on Immune Function and Quality of Life in Colorectal Cancer
Dietary Fiber and Probiotics in Advanced Colorectal Cancer
Effect of a Resilience Model-Based Program for Patients With Newly Diagnosed Colorectal Cancer
Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer
Illness Perception and Quality of Life in Colorectal Cancer With Ascites
A Beta-only IL-2 ImmunoTherapY Study